$5.03
4.19% yesterday
Nasdaq, Apr 02, 10:10 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$5.03
+1.15 29.64% 1M
-4.71 48.38% 6M
-3.31 39.69% YTD
-19.17 79.21% 1Y
-99.57 95.19% 3Y
-546.64 99.09% 5Y
-1,529.05 99.67% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.22 4.19%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $49.24m
Enterprise Value $341.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.08
P/S ratio (TTM) P/S ratio 0.59
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 184.12%
Revenue (TTM) Revenue $83.81m
EBIT (operating result TTM) EBIT $-267.70m
Free Cash Flow (TTM) Free Cash Flow $-262.62m
Cash position $62.34m
EPS (TTM) EPS $-24.86
P/E forward negative
P/S forward 0.18
EV/Sales forward 1.26
Short interest 20.58%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a bluebird bio, Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a bluebird bio, Inc. forecast:

Buy
20%
Hold
80%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
84 84
184% 184%
100%
- Direct Costs 97 97
169% 169%
116%
-13 -13
101% 101%
-16%
- Selling and Administrative Expenses 99 99
35% 35%
118%
- Research and Development Expense 94 94
45% 45%
112%
-206 -206
37% 37%
-246%
- Depreciation and Amortization 61 61
411% 411%
73%
EBIT (Operating Income) EBIT -268 -268
22% 22%
-319%
Net Profit -241 -241
18% 18%
-287%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Positive
Reuters
6 days ago
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Positive
Market Watch
6 days ago
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
Neutral
Business Wire
6 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previousl...
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 248
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today